PL397821A1 - Związek1-acetylo-6-fluoro-2-indolinon - Google Patents

Związek1-acetylo-6-fluoro-2-indolinon

Info

Publication number
PL397821A1
PL397821A1 PL397821A PL39782103A PL397821A1 PL 397821 A1 PL397821 A1 PL 397821A1 PL 397821 A PL397821 A PL 397821A PL 39782103 A PL39782103 A PL 39782103A PL 397821 A1 PL397821 A1 PL 397821A1
Authority
PL
Poland
Prior art keywords
fluoro
acetyl
indolinone compound
indolinone
compound
Prior art date
Application number
PL397821A
Other languages
English (en)
Inventor
Gerald Jürgen Roth
Armin Heckel
Jörg Kley
Thorsten Lehmann-Lintz
Frank Hilberg
Ulrike Tontsch-Grunt
Meel Jacobus van (Jacques) C.A.
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/de
Priority claimed from DE10328533A external-priority patent/DE10328533A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of PL397821A1 publication Critical patent/PL397821A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL397821A 2002-07-23 2003-07-22 Związek1-acetylo-6-fluoro-2-indolinon PL397821A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (de) 2002-07-23 2002-07-23 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
DE10328533A DE10328533A1 (de) 2003-06-24 2003-06-24 In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
PL397821A1 true PL397821A1 (pl) 2012-03-12

Family

ID=30771725

Family Applications (2)

Application Number Title Priority Date Filing Date
PL397821A PL397821A1 (pl) 2002-07-23 2003-07-22 Związek1-acetylo-6-fluoro-2-indolinon
PL03374879A PL374879A1 (pl) 2002-07-23 2003-07-22 Pochodne indolinonu podstawione w pozycji 6, sposób ich wytwarzania i ich zastosowanie jako leki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL03374879A PL374879A1 (pl) 2002-07-23 2003-07-22 Pochodne indolinonu podstawione w pozycji 6, sposób ich wytwarzania i ich zastosowanie jako leki

Country Status (24)

Country Link
EP (1) EP1523473B1 (pl)
JP (1) JP4401291B2 (pl)
KR (2) KR20120003025A (pl)
CN (1) CN1318403C (pl)
AR (1) AR041188A1 (pl)
AU (2) AU2003254557B2 (pl)
BR (1) BR0312799A (pl)
CA (1) CA2493436C (pl)
DK (1) DK1523473T3 (pl)
EA (1) EA008623B1 (pl)
EC (1) ECSP055567A (pl)
ES (1) ES2409062T3 (pl)
HR (1) HRP20050069A2 (pl)
IL (1) IL166404A0 (pl)
MX (1) MXPA04012937A (pl)
MY (1) MY138141A (pl)
NO (1) NO20050937L (pl)
PE (1) PE20040701A1 (pl)
PL (2) PL397821A1 (pl)
RS (1) RS20050047A (pl)
SA (1) SA03240430B1 (pl)
TW (1) TWI343375B (pl)
UY (1) UY27903A1 (pl)
WO (1) WO2004009547A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (es) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
NZ563448A (en) * 2005-04-28 2011-01-28 Boehringer Ingelheim Int Benzofuranone derivatives for treating inflammatory diseases
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
MX2010007950A (es) * 2008-01-25 2010-08-04 Boehringer Ingelheim Int Formas salinas de un derivado de 6-fluoro-1,2-dihidro-2-oxo-3h-ind ol-3-ilideno, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
JP2011510031A (ja) * 2008-01-25 2011-03-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 6−フルオロ−1,2−ジヒドロ−2−オキソ−3h−インドール−3−イリデン誘導体の製造方法
JP5651110B2 (ja) 2008-07-29 2015-01-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物
EP2910547B1 (en) * 2012-10-17 2017-06-14 Okayama University Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug
US9642851B2 (en) 2012-12-06 2017-05-09 Kbp Biosciences Co., Ltd. Indolinone derivative as tyrosine kinase inhibitor
CN105461609B (zh) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 一种尼达尼布的制备方法
CN114213396B (zh) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 一种吲哚-2-酮类化合物及其制备方法与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200100184A (et) * 1998-09-25 2002-08-15 Boehringer Ingelheim Pharma Kg Uudsed asendatud indolinoonid inhibeeriva toimegamitmesugustele kinaasidele ja tsükliin/CDK kompleksidele
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US7005444B2 (en) * 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors
US20030225152A1 (en) * 2001-09-27 2003-12-04 Andrews Steven W. 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
AU2003254557A1 (en) 2004-02-09
CN1318403C (zh) 2007-05-30
EA200500148A1 (ru) 2005-08-25
MY138141A (en) 2009-04-30
EA008623B1 (ru) 2007-06-29
ES2409062T3 (es) 2013-06-24
RS20050047A (sr) 2007-09-21
PL374879A1 (pl) 2005-11-14
JP4401291B2 (ja) 2010-01-20
KR20050052456A (ko) 2005-06-02
TW200413314A (en) 2004-08-01
HK1081554A1 (en) 2006-05-19
AU2010202845A1 (en) 2010-07-22
KR20120003025A (ko) 2012-01-09
WO2004009547A1 (de) 2004-01-29
BR0312799A (pt) 2005-05-03
EP1523473B1 (de) 2013-02-27
HRP20050069A2 (en) 2005-12-31
IL166404A0 (en) 2006-01-15
JP2005533841A (ja) 2005-11-10
AR041188A1 (es) 2005-05-04
AU2003254557B2 (en) 2010-07-22
UY27903A1 (es) 2004-02-27
TWI343375B (en) 2011-06-11
MXPA04012937A (es) 2005-05-16
EP1523473A1 (de) 2005-04-20
SA03240430B1 (ar) 2008-03-23
NO20050937L (no) 2005-02-21
PE20040701A1 (es) 2004-11-30
CA2493436A1 (en) 2004-01-29
ECSP055567A (es) 2005-04-18
DK1523473T3 (da) 2013-06-03
CA2493436C (en) 2011-11-08
CN1668589A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
GB0229015D0 (en) New Compound
EP1558585A4 (en) NEUROLOGICALLY ACTIVE COMPOUNDS
PL372622A1 (pl) Związki oksoazabicykliczne
GB0200283D0 (en) Compounds
GB0221828D0 (en) Novel compound
GB0221829D0 (en) Novel compound
GB0204241D0 (en) Compound
AU2003216859A8 (en) Amidoacetonitrile compounds
GB0216224D0 (en) Compounds
GB0207323D0 (en) Compounds
GB0224830D0 (en) Compound
GB0216383D0 (en) Compounds
GB0203778D0 (en) Compounds
GB0213027D0 (en) Compound
GB0213011D0 (en) Compounds
GB0216985D0 (en) Compounds
GB0218326D0 (en) Compounds
GB0207637D0 (en) Novel compound
AU2003275480A8 (en) Compounds
GB0203811D0 (en) Compounds
GB0213014D0 (en) Compound
GB0229075D0 (en) Compound
GB0214267D0 (en) Compound
GB0209274D0 (en) Compound
GB0217506D0 (en) Compound

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)